# Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

> **NCT06568718** · NA · COMPLETED · sponsor: **NPO Petrovax** · enrollment: 229 (actual)

## Conditions studied

- Lower Urinary Tract Symptoms
- Prostatic Hyperplasia

## Interventions

- **DRUG:** bovhyaluronidase azoximer
- **DRUG:** tamsulosin

## Key facts

- **NCT ID:** NCT06568718
- **Lead sponsor:** NPO Petrovax
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-20
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-02-09
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06568718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06568718, "Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06568718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*